During the past decade, CHLO, EPE - Hospital S. Francisco Xavier conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 8 clinical trials were completed, i.e. on average, 72.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 7 clinical trials were completed. i.e. 116.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHLO, EPE - Hospital S. Francisco Xavier" #1 sponsor was "Boehringer Ingelheim" with 5 trials, followed by "Bayer" with 4 trials sponsored, "Janssen Pharmaceutica N.V., Belgium" with 1 trials sponsored, "Janssen Research & Development, LLC" with 1 trials sponsored and "SOLTI Breast Cancer Research Group" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHLO, EPE - Hospital S. Francisco Xavier" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "CINTESIS - Center for Health Technology and Services Research" with 1 trials as a collaborator, "CUF Academic and Research Medical Center" with 1 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator and "Centro Hospitalar Universitário São João" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "CHLO, EPE - Hospital S. Francisco Xavier" are "Heart Failure" (3 trials), "Atrial Fibrillation" (1 trials), "Breast Cancer Stage II" (1 trials), "COVID-19" (1 trials) and "Chronic Heart Failure With Preserved Ejection Fraction" (1 trials). Many other conditions were trialed in "CHLO, EPE - Hospital S. Francisco Xavier" in a lesser frequency.

Most popular intervention types in "CHLO, EPE - Hospital S. Francisco Xavier" are "Drug" (11 trials), "Other" (2 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Empagliflozin" (2 trials), "Apalutamide" (1 trials), "BAY 1753011" (1 trials) and "Bortezomib" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHLO, EPE - Hospital S. Francisco Xavier" are 12 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CHLO, EPE - Hospital S. Francisco Xavier". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in CHLO, EPE - Hospital S. Francisco Xavier, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHLO, EPE - Hospital S. Francisco Xavier, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".